The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://tayarike423733.wikidirective.com/7997649/retatrutide_vs_tirzepatide_a_comparative_analysis